Monopar Therapeutics
MNPR
MNPR
14 hedge funds and large institutions have $92K invested in Monopar Therapeutics in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less ownership
Funds ownership: →
50% less capital invested
Capital invested by funds: $182K → $92K (-$90.2K)
Holders
14
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$16K | |
| 2 | +$9K | |
| 3 | +$4.87K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.02K |
| 5 |
Millennium Management
New York
|
+$3.51K |
Top Sellers
| 1 | -$55.8K | |
| 2 | -$15.3K | |
| 3 | -$14.4K | |
| 4 |
HF
HRT Financial
New York
|
-$7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$36 |